{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:03:06Z","timestamp":1761894186510},"reference-count":24,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.leukres.2005.10.002","type":"journal-article","created":{"date-parts":[[2005,11,9]],"date-time":"2005-11-09T12:15:49Z","timestamp":1131538549000},"page":"681-685","source":"Crossref","is-referenced-by-count":6,"title":["Modified Magrath IVAC regimen as second-line therapy for relapsed or refractory aggressive non-Hodgkin's lymphoma in developing countries: The experience of a single center in Brazil"],"prefix":"10.1016","volume":"30","author":[{"given":"Juliana","family":"Pereira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Bellesso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Fernando","family":"Pracchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abrah\u00e3o Elias Hallack","family":"Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Beitler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina Martins de Almeida","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia Cristina Santos","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Enrique","family":"Dorlhiac-Llacer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederico Luiz","family":"Dulley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalton","family":"Chamone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2005.10.002_bib1","unstructured":"Mirra AP, Latorre MRDO, Veneziano DR, editors. Incid\u00eancia de c\u00e2ncer no munic\u00edpio de S\u00e3o Paulo, Brasil: 1997\u20131998. Mortalidade de c\u00e2ncer no munic\u00edpio de S\u00e3o Paulo, Brasil, tend\u00eancia no per\u00edodo 1969\u20131998. S\u00e3o Paulo, Minist\u00e9rio da Sa\u00fade, 2001."},{"key":"10.1016\/j.leukres.2005.10.002_bib2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.10.002_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","article-title":"Effective salvage therapy for lymphoma with cisplatin in combination with high- dose Ara-C and dexamethasone (DHAP)","volume":"71","author":"Velasquez","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.002_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V60.3.693.693","article-title":"IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy","volume":"60","author":"Cabanillas","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.002_bib5","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1200\/JCO.1999.17.12.3776","article-title":"Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant eligible patients with non-Hodgkin's lymphoma","volume":"17","author":"Moskowitz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2005.10.002_bib6","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2005.10.002_bib7","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.10.002_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.1999.17.1.423","article-title":"International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury","volume":"17","author":"Shipp","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2005.10.002_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1600-0609.2004.00294.x","article-title":"ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma\u2014the Nordic Lymphoma Group experience","volume":"73","author":"Jekerman","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.leukres.2005.10.002_bib10","first-page":"33","article-title":"Additional chemotherapy agents improve treatment outcome for children and adults with advanced B-cell lymphomas","volume":"25","author":"Adde","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1016\/j.leukres.2005.10.002_bib11","doi-asserted-by":"crossref","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting, Airlie House, Virginia, November, 1997. Histopathology 2000; 36:69\u201386.","DOI":"10.1046\/j.1365-2559.2000.00895.x"},{"key":"10.1016\/j.leukres.2005.10.002_bib12","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamilin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2005.10.002_bib13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2005.10.002_bib14","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol a group d\u2019Etude des lymphomes de I\u2019Adulte study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2005.10.002_bib15","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.leukres.2005.10.002_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.leukres.2005.10.002_bib17","doi-asserted-by":"crossref","unstructured":"Peto R, Peto J. Asymptotically efficient rank invariation test procedures (with discussion). J R Stat Soc 1972;135:185.","DOI":"10.2307\/2344317"},{"key":"10.1016\/j.leukres.2005.10.002_bib18","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2000.18.21.3633","article-title":"Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH","volume":"18","author":"Gutierrez","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2005.10.002_bib19","first-page":"1028","article-title":"High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma","volume":"87","author":"Salar","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2005.10.002_bib20","first-page":"1366","article-title":"Scotland And Newcastle lymphoma group study. A pilot study of CODOX-M\/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma. A Scotland and Newcastle lymphoma group study","volume":"88","author":"Davidson","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2005.10.002_bib21","first-page":"311","article-title":"Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma","volume":"4","author":"Moskowitz","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2005.10.002_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2005.10.002_bib23","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1200\/JCO.2005.09.137","article-title":"Introduction of combined CHOP Plus rituximab therapy dramatically improved outcome of diffuse large b-cell lymphoma in British Columbia","author":"Sehn","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2005.10.002_bib24","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1182\/blood-2003-11-3911","article-title":"Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma","volume":"103","author":"Kewalramani","year":"2004","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605003772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212605003772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T19:12:33Z","timestamp":1586545953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212605003772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0145212605003772"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2005.10.002","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}